On Thursday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: SanDisk Corp. (NASDAQ:SNDK), Enova International, Inc. (NYSE:ENVA), Yamana Gold, Inc. (NYSE:AUY), Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)

SanDisk Corp. (NASDAQ:SNDK), with shares declined -18.45%, closed at $66.20, hitting new 52-week low of $65.45.

Enova International, Inc. (NYSE:ENVA), with shares dropped -17.98%, settled at $19.52.

Yamana Gold, Inc. (NYSE:AUY), with shares dipped -3.23%, and closed at $3.89.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), plummeted -16.86%, and closed at $14.

Latest NEWS regarding these Stocks are depicted underneath:

SanDisk Corp. (NASDAQ:SNDK)

SanDisk Corp. (SNDK), declared that it anticipates its proceed for the first fiscal quarter, which will end on March 29, 2015, to be about $1.3 billion, depending on final sell-through results, contrast to the formerly forecasted proceed range of $1.40 billion to $1.45 billion.

The change in first quarter proceed estimate is primarily due to certain product qualification delays, lower than predictable sales of enterprise products and lower pricing in some areas of the business. The Corporation anticipates continued influence to its 2015 financial results from these factors in addition to the formerly identified supply challenges, and now forecasts 2015 proceed to be lower than the previous guidance.

Other forecasts for the quarter and the year are withdrawn, and the Corporation will provide an update during its first quarter earnings call on April 15, 2015. SanDisk will also replan its formerly declared May 2015 Investor Day to a later date.

“We are disappointed with our financial outlook,” said Sanjay Mehrotra, president and chief executive officer, SanDisk. “We will work through these headwinds, leveraging our compelling product roadmap and broadening customer base. We believe our growth prospects remain strong and we are encouraged by the progress we are making in our 3D NAND technology.”

Enova International, Inc. (NYSE:ENVA)

Enova International, Inc. (ENVA), declared that it supports the Consumer Financial Protection Bureau (CFPB) efforts to provide a well-regulated market for consumers who need access to short-term credit.

“Enova has long supported regulation that ensures providers of credit for middle and working class consumers, whether they are banks or other lenders, follow a ordinary set of rules that provide protection for consumers while also ensuring credit is accessible when they need it,” said David Fisher, CEO of Enova International. “We have championed industry best practices, and we encourage the CFPB, as it starts the process of proposing rules, to base those rules on data that reflect the realities of consumer credit needs and the credit marketplace.”

The CFPB states that it is presently considering several proposals and that it has not accomplished an analysis of potential influence to the industry and consumers, so it is difficult for Enova to estimate the potential influence to its business at this time. In addition, the outline released recently is only a proposal, and the final rules could change significantly.

Enova is reaffirming its full year 2015 guidance. The corporation continues to expect total proceed of $750 million to $830 million and Adjusted EBITDA of $180 million to $240 million. Please see our earnings release for the year ended December 31, 2014, as issued on February 3, 2015, for a reconciliation of revenue from operations to Adjusted EBITDA for such periods.

Enova International, Inc. provides online financial services to alternative credit consumers in the United States, the United Kingdom, Australia, Canada, Brazil, and China. It offers short-term consumer loans, installment loans, and line of credit accounts under the CashNetUSA, NetCredit, Headway Capital, QuickQuid, QuickQuid FlexCredit, Pounds to Pocket, OnStride Financial, DollarsDirect, Simplic, and YouXinYi brands. The corporation is headquartered in Chicago, Illinois.

Yamana Gold, Inc. (NYSE:AUY)

Mirasol is happy to declare it has signed a joint venture contract with Yamana Gold, Inc. (AUY), granting Yamana the option to attain up to a 75% interest in the Gorbea Belt Projects.

The option granted to Yamana will be exercisable in three stages over a seven year period.

• The joint venture contract establishes Yamana as a planned partner in the exploration and potential development of Mirasol’s Gorbea Belt Projects, counting the Atlas and Titan projects
• The Contract is subject to a 45 day due diligence review period, and grants Yamana the option to attain up to a 75% interest in the Project over a seven year period.
• The first earn-in option to a 51% interest requires a spend commitment of US$10,000,000 and cash payments to Mirasol of US$2,000,000 over four years.
• The first year spend commitment is US$2,000,000 , counting geophysical surveys and 2,000 metres of exploration drilling at the Atlas and Titan projects.

Yamana Gold Inc. is engaged in gold mining and related activities, counting exploration, extraction, processing, and reclamation. The corporation has precious metal properties and land positions throughout the Americas, counting in Brazil, Chile, Argentina, and Mexico.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)

Sucampo Pharmaceuticals, Inc. (SCMP), declared the pricing of an underwritten public offering of 4,000,000 shares of its class A ordinary stock by selling stockholders, offered at a price to the public of $14.00 per share for an aggregate offering of $56.0 million of class A ordinary stock. All shares will be offered by S&R Technology Holdings, LLC, S&R Foundation, Dr. Sachiko Kuno and Dr. Ryuji Ueno. Sucampo will not sell any shares or receive any proceeds from the offering. The underwriters have been granted a 30-day option to purchase up to an aggregate of 600,000 additional shares of class A ordinary stock. The offering is predictable to close on or about March 31, 2015, subject to customary closing conditions.

Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. Guggenheim Securities, LLC is acting as co-manager.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical corporation, focuses on the research and development of proprietary drugs in the Americas, Europe, and Asia. It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders, in addition to other therapeutic applications of drug technologies.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.